IP Library Granted Patent US 8,679,743
Granted Patent B2
US 8,679,743 · App. 13/213,390 · Granted Mar 25, 2014

Reducing IRF4, DUSP22, or FLJ43663 polypeptide expression

Inventors: Andrew L. Feldman (Rochester, MN); Ahmet Dogan (Rochester, MN); George Vasmatzis (Oronoco, MN); Mark Law (Rochester, MN); David I. Smith (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,679,743
App. No.
13/213,390
Granted
Mar 25, 2014
Kind
B2
Abstract

This document relates to the activity of interferon regulatory factor 4 (IRF4) in T-cell lymphomas. For example, methods and materials involved in reducing the expression of an IRF4 polypeptide in T-cell lymphoma cells and identifying agents having the ability to reduce expression of an IRF4 polypeptide in T-cell lymphoma cells are provided. This document also relates to reducing DUSP22 or FLJ43663 polypeptide activity in T-cell lymphomas. For example, methods and materials involved in reducing the expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells and identifying agents having the ability to reduce expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells are provided.

Claims (5)

1. A method for assessing a lymphoma of a mammal, wherein said method comprises:

(a) performing breakapart fluorescence in situ hybridization using a first probe that hybridizes to a 6p25.3 chromosome region and a second probe that hybridizes to a 6p25.3 chromosome region to detect a DUSP22 translocation within said lymphoma, wherein said first and second probes comprise different fluorescent signals, and

(b) classifying said mammal as having anaplastic large-cell lymphoma.

2. The method of claim 1 , wherein said mammal is a human.

3. The method of claim 1 , wherein said method comprises classifying said mammal as having cutaneous anaplastic large-cell lymphoma.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2012
From: FELDMAN, ANDREW L.; DOGAN, AHMET; VASMATZIS, GEORGE; LAW, MARK; SMITH, DAVID I.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 028887/0919 →
CONFIRMATORY LICENSE Recorded Sep 15, 2011
From: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026915/0439 →
Continuity (3)
Division 12782484 · May 18, 2010
Provisional Application 61179201 · May 18, 2009
Related Publication 20110306517A1 · Dec 15, 2011